MEDANTA · NSE
Global Health Limited
₹1,480.2
+0.13% (+₹1.9)
Prev. close
₹1,478.3
Volume
2,65,365
Delivery %
47.3%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Axis Direct recommends buying Global Health with a target of ₹1,615, citing strong earnings momentum and favorable indus…” | ETMarkets AnalysisETMarkets.com | Global Health | PENDING | |
| “Bullish on Global Health (Medanta), recommending a buy at ₹1480 with a target of ₹1585 and a stop loss at ₹1428. The sto…” | Sumeet BagadiaChoice Equity Broking | Global Health | MISS | |
| “Bullish on Global Health Ltd, recommending a buy at ₹1,380–1,400 with a target price of ₹1,540 in two to three months an…” | Marketsmith India AnalysisMarketsmith India | Global Health Ltd | MISS | |
| “Recommends buying Global Health Ltd (Medanta) at ₹1,386.40, with a stop-loss at ₹1,339 and a target of ₹1,480. The stock…” | Sumeet BagadiaChoice Equity Broking | Global Health Ltd | MISS | |
| “Bullish on Global Health Ltd, recommending a buy between ₹1,350-1,370 with a target price of ₹1,560 in two to three mont…” | Marketsmith India AnalysisMarketsmith India | Global Health Ltd | MISS | |
| “Bullish on Global Health Ltd (Medanta), recommending a buy at ₹1,423.20 with a target of ₹1,540 and a stop loss at ₹1,36…” | Ankush BajajIndependent | Global Health Ltd | MISS | |
| “Bullish on Medanta, recommending a buy above 1420 with a target of 1500 and a stop-loss at 1379. The stock shows a stron…” | Rupak DeLKP Securities | Global Health Ltd | MISS | |
| “Bullish on Global Health (Medanta), recommending a buy at ₹1338 with a target of ₹1432 and a stop loss at ₹1290, based o…” | Sumeet BagadiaChoice Equity Broking | Global Health Ltd | MISS | |
| “Bullish on Global Health (MEDANTA), recommending a buy around ₹1327.40 with a stop loss at ₹1280 for a target price of ₹…” | Sumeet BagadiaChoice Equity Broking | Global Health Ltd | HIT | |
| “Bullish on Global Health Ltd (Medanta) with a target price of ₹1,560 in two to three months, recommending buying at ₹1,3…” | Marketsmith India AnalysisMarketsmith India | Global Health Ltd | MISS | |
| “Emkay Global Financial has a 'Reduce' rating on Global Health, setting a target price of ₹1175. This indicates a bearish…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Global Health Ltd | HIT | |
| “Recommends buying Global Health at ₹1227.10, targeting ₹1313 with a stop loss at ₹1184, based on technical breakout sign…” | Sumeet BagadiaChoice Equity Broking | Global Health Ltd | MISS | |
| “Bullish on Global Health (MEDANTA), recommending a buy with a target of ₹1,270 and a stop-loss below ₹1,164. After a dec…” | Anand JamesGeojit Investments Limited | Global Health Ltd | MISS | |
| “Recommends buying Global Health Ltd today at ₹1,269.95, with a target price of ₹1,370 and a stop loss at ₹1,210, based o…” | Sumeet BagadiaChoice Equity Broking | Global Health Ltd | MISS | |
| “Recommends buying Medanta above ₹1,235, setting a stop loss at ₹1,210 and targets between ₹1,315-1,345 for April 2nd. Th…” | Raja VenkatramanNeoTrader | Global Health Ltd | MISS | |
| “Axis Securities recommends a 'BUY' on Global Health (Medanta) with a target price of ₹1,390, implying a 10% upside from …” | Axis Securities AnalysisAxis Securities | Medanta - The Global Health Ltd | HIT | |
| “Bullish on Global Health Ltd (Medanta) for short-to-medium term, targeting ₹1,500 in the coming weeks. The stock is show…” | ETMarkets AnalysisETMarkets.com | Global Health Ltd | MISS | |
| “Bullish on Medanta (Global Health Ltd) with a target of ₹1,310 and a stop loss at ₹1,168. This chart stands out as many …” | Sagar DoshiNuvama Professional Clients Group | Medanta (Global Health Ltd) | MISS | |
| “Bullish on Global Health, recommending a buy at ₹1213.4 with a target of ₹1300 and a stop loss at ₹1170, based on strong…” | Sumeet BagadiaChoice Equity Broking | Global Health Ltd | MISS | |
| “JM Financial has a 'buy' call on Global Health (MEDANTA) with a target price of Rs 1,465, expecting the stock to reach t…” | JM Financial AnalysisJM Financial Institutional Securities | Global Health Ltd | MISS | |
| “Bullish on MEDANTA, recommending a buy at ₹1,212 with targets between ₹1,288-1,310 and a stop loss at ₹1,168. The call i…” | Ankush BajajIndependent | Global Health Ltd | HIT | |
| “Recommends buying Medanta at ₹1,212 with targets of ₹1,288-1,310 and a stop loss at ₹1,168. The RSI at 63.17 suggests up…” | Ankush BajajIndependent | Global Health Ltd | HIT | |
| “Bullish on Global Health (Medanta) for the short term, targeting ₹1,324 with a stop loss at ₹1,138. The stock has witnes…” | Vishnu Kant UpadhyayMaster Capital Services | Global Health Ltd | MISS | |
| “Bullish on Global Health (Medanta) for intraday trading, recommending a buy at ₹1206.4 with a target of ₹1290 and a stop…” | Sumeet BagadiaChoice Equity Broking | Global Health Limited | MISS |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Medanta in the near term, with a target of ₹1,500 and support at ₹1,379. The stock has shown a decisive break…” | Rupak DeLKP Securities | Global Health Ltd | — |
Fundamentals
About Global Health Limited
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, lab and pathology, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinions, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup services. In addition, the company is involved in trading pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Pankaj Prakash Sahni
Headquarters
Gurugram
Employees
12,600
Website
medanta.orgExchange
View on NSE ↗Key stats
Market cap
₹37,651.01 Cr
P/E ratio (TTM)
61.0
Dividend yield
0.04%
EPS (TTM)
₹22.98
Beta (1Y · daily vs NIFTY 50)
0.77
Beta (5Y · monthly vs NIFTY 50)
0.54
Shares float
8.85 Cr
EPS · quarter ended Jun 2026
₹5.90
Financial Performance
01 · Financials
EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (revenue was nil or not reported).
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹2,694.25 Cr | ₹3,275.11 Cr | ₹3,692.32 Cr | ₹4,410.27 Cr | |
EBITDA | — | — | ₹677.12 Cr | ₹873.74 Cr | ₹906.26 Cr | ₹1,016.67 Cr |
| ₹29.00 Cr | ₹196.00 Cr | ₹326.08 Cr | ₹478.19 Cr | ₹481.44 Cr | ₹556.46 Cr | |
Diluted EPS | — | — | ₹10.15 | ₹17.8 | ₹17.18 | ₹18.42 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2023 could not be checked against the company's own annual report: this page shows ₹326.08 Cr while the annual report gives ₹263.25 Cr (19.3% apart).
EBITDA for Mar 2023 could not be checked against the company's own annual report: this page shows ₹677.12 Cr while the annual report gives ₹463.96 Cr (31.5% apart).
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,694.00 Cr | ₹3,146.00 Cr | ₹4,097.00 Cr | ₹4,280.00 Cr | ₹4,766.00 Cr | ₹5,905.00 Cr | |
| — | — | ₹1,121.95 Cr | ₹801.87 Cr | ₹717.73 Cr | ₹1,190.05 Cr | |
Stockholders' equity | ₹1,383.00 Cr | ₹1,616.00 Cr | ₹2,429.00 Cr | ₹2,906.00 Cr | ₹3,387.00 Cr | ₹3,962.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹242.00 Cr | ₹311.00 Cr | ₹645.00 Cr | ₹612.00 Cr | ₹624.00 Cr | ₹714.00 Cr | |
Investing cash flow | — | — | ₹-342.34 Cr | ₹-440.80 Cr | ₹-720.94 Cr | ₹-1,089.11 Cr |
| — | — | ₹345.64 Cr | ₹-513.92 Cr | ₹-97.23 Cr | ₹271.85 Cr | |
Capital expenditure | ₹-146.00 Cr | ₹-274.00 Cr | ₹-236.00 Cr | ₹-279.00 Cr | ₹-517.00 Cr | ₹-838.00 Cr |
End cash position | — | — | ₹767.24 Cr | ₹424.61 Cr | ₹230.20 Cr | ₹127.33 Cr |
Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 22–Mar 23(3Q) | Jun 23 | Sep 23 | Dec 23 | Mar 24–Sep 24(3Q) | Dec 24–Mar 25(2Q) | Jun 25–Dec 25(3Q) | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.08% | 33.07% | 33.06% | 33.05% | 33.04% | 33.03% | 33.01% | 33.01% | 33.00% |
| Public | 66.92% | 66.93% | 66.94% | 66.95% | 66.96% | 66.97% | 66.93% | 66.92% | 66.91% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 0.08% | 0.09% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Global Health Limited | ₹34,911.78 Cr | ₹1,325.8 | 62.9 | 8.81 | 14.0% | 0.30 | +18.7% | +4.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
UAE ranks joint first globally in personal safety, scores 96% in Gallup Global Safety Report
Gulf News · 2 days ago
As Global Health Aid Dries Up, Non-Profit Drug Development Faces New Challenges
Global Health Limited faces a shrinking funding environment as donor governments cut global health budgets, with the Gates Foundation reducing PDP grants by nearly a quarter in 2024 and the UK’s support rising only modestly. This financial squeeze threatens the development pipeline of neglected‑disease medicines, as 12 product development partnerships report nearly 300 candidates in various trial stages. The uncertainty may force a “natural selection” of the most viable partnerships, potentially curtailing progress against malaria, tuberculosis and other tropical diseases.